MO
Molecular Partners AG
MOLN · NASDAQ
$4.21 +4.73% (+$0.19)
1M -4.32%
Market Cap CHF 129.9M
P/E Ratio -
Div. Yield -
ROE 65.62%
Bulios Fair Price
$2.77
34.2% downside
Current Price
$4.21
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MOLN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
90 /100
Cheap P/B 1.90x
P/E N/A
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 30.09%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 72.64%
Asset turnover 0.00x
ROE 65.62%
Debt
69 /100
Low Debt/Equity 0.05x
Int. coverage -1,954.60x
Current ratio 9.42x
Stability
28 /100
Unstable Beta 0.69x
Profitable years 0
Rev. volatility 39.74%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MOLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Patrick Amstutz
Employees
134
Headquarters
Schlieren
Upcoming events
29 OCT
Earnings
Upcoming earnings report